Biography
Dr. Jishuai Zhang
Dr. Jishuai Zhang
Shenzhen PREGENE Biopharma Company, Ltd, China
Title: Nanobody's application in cell therapy
Abstract: 
The single domain antibody and its application in CART therapy
Bullet points: 
The introduction for single-domain antibody.
The development and clinical effect of CART targeting BCMA using humanized single domain antibody as the antigen recognition domain.
Biography: 
As the Chief Scientific Officer in Shenzhen PREGENE Biopharma Company, Ltd, Dr. Zhang Jishuai graduated from Zhengzhou University, receiving a B.S. degree in clinical medicine. Then, he got his M.S. degree in molecular immunology in the Fourth Military Medical University, and Ph.D. in genetics in Beijing Institute of Biotechnology. After that, he obtained the postdoctoral training in the Hormel Institute in the University of Minnesota. As an expert on tumor biology, Dr. Zhang once did detailed study on tumor gene function (including tumor initiation, differentiation and metastasis), about which he published over 20 papers. In 2016, he founded the PREGENE Company and acted as the Chief Scientific Officer, from which he began the research and development of CART drug. Having built a platform of “Nanobody discovery, CART research and drug development”, PREGENE is now mainly focused on CART therapy for hematologic tumors.